Co-Diagnostics, Inc. Common Stock Net Assets
Co-Diagnostics, Inc. Common Stock net assets. Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has net assets worth $16.04 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.50 Million) and total liabilities ($5.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CODX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.04 Million |
| % of Total Assets | 74.62% |
| Annual Growth Rate | 57.58% |
| 5-Year Change | -84.66% |
| 10-Year Change | N/A |
| Growth Volatility | 1322.82 |
Net Assets of Co-Diagnostics, Inc. Common Stock (2014–2025)
Net assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. This chart illustrates how Co-Diagnostics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Co-Diagnostics, Inc. Common Stock (CODX) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual net assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. For live market cap and overall valuation, see how much is Co-Diagnostics, Inc. Common Stock worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $20.63 Million | -62.02% |
| 2024-12-31 | $54.31 Million | -36.86% |
| 2023-12-31 | $86.01 Million | -24.89% |
| 2022-12-31 | $114.52 Million | -14.84% |
| 2021-12-31 | $134.48 Million | +101.62% |
| 2020-12-31 | $66.70 Million | +3739.19% |
| 2019-12-31 | $1.74 Million | +264.08% |
| 2018-12-31 | $-1.06 Million | -127.50% |
| 2017-12-31 | $3.85 Million | +228.58% |
| 2016-12-31 | $-2.99 Million | -160.99% |
| 2015-12-31 | $-1.15 Million | -927.67% |
| 2014-12-31 | $138.63K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Co-Diagnostics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7888218100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Co-Diagnostics, Inc. Common Stock Net Assets Breakdown (December 2025)
Co-Diagnostics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $67.70K | 0.33% |
| Other Components | $100.93 Million | 489.29% |
| Total Equity | $20.63 Million | 100.00% |
Co-Diagnostics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xaar plc
LSE:XAR
|
$1.40 Million |
|
Condmag Brasov
RO:COMI
|
$1.40 Million |
|
Beyon 3D Ltd
TA:BYON
|
$1.40 Million |
|
RED LAKE GOLD INC.
F:P11A
|
$1.40 Million |
|
Savannah Energy PLC
LSE:SAVE
|
$1.40 Million |
|
GO2 People Ltd
AU:GO2
|
$1.40 Million |
|
Pineapple Financial Inc.
NYSE:PAPL
|
$1.40 Million |
|
Anatara Lifesciences Ltd
AU:ANR
|
$1.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Co-Diagnostics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 54,311,918 to 20,628,664, a change of -33,683,254 (-62.0%).
- Net loss of 46,895,936 reduced equity.
- New share issuances of 11,799,083 increased equity.
- Other comprehensive income decreased equity by 418,442.
- Other factors increased equity by 1,832,041.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.90 Million | -227.33% |
| Share Issuances | $11.80 Million | +57.2% |
| Other Comprehensive Income | $-418.44K | -2.03% |
| Other Changes | $1.83 Million | +8.88% |
| Total Change | $- | -62.02% |
Book Value vs Market Value Analysis
This analysis compares Co-Diagnostics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.72x to 0.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.53 | $0.38 | x |
| 2015-12-31 | $-0.10 | $0.38 | x |
| 2016-12-31 | $-8.03 | $0.38 | x |
| 2017-12-31 | $10.54 | $0.38 | x |
| 2018-12-31 | $-2.54 | $0.38 | x |
| 2019-12-31 | $3.11 | $0.38 | x |
| 2020-12-31 | $71.46 | $0.38 | x |
| 2021-12-31 | $134.91 | $0.38 | x |
| 2022-12-31 | $109.14 | $0.38 | x |
| 2023-12-31 | $87.93 | $0.38 | x |
| 2024-12-31 | $53.71 | $0.38 | x |
| 2025-12-31 | $15.51 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Co-Diagnostics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -227.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7533.62%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.20x
- Recent ROE (-227.33%) is below the historical average (-129.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -756.07% | 0.00% | 0.00x | 1.87x | $-1.06 Million |
| 2015 | 0.00% | -20431.68% | 0.03x | 0.00x | $-1.93 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.63 Million |
| 2017 | -180.73% | -90827.88% | 0.00x | 1.21x | $-7.34 Million |
| 2018 | 0.00% | -15714.27% | 0.03x | 0.00x | $-6.17 Million |
| 2019 | -356.63% | -2882.00% | 0.10x | 1.28x | $-6.37 Million |
| 2020 | 63.69% | 56.98% | 1.05x | 1.07x | $35.81 Million |
| 2021 | 27.26% | 37.45% | 0.61x | 1.19x | $23.21 Million |
| 2022 | -12.43% | -41.61% | 0.28x | 1.07x | $-25.69 Million |
| 2023 | -41.08% | -518.68% | 0.07x | 1.11x | $-43.93 Million |
| 2024 | -69.30% | -961.37% | 0.06x | 1.18x | $-43.07 Million |
| 2025 | -227.33% | -7533.62% | 0.03x | 1.20x | $-48.96 Million |
Industry Comparison
This section compares Co-Diagnostics, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Co-Diagnostics, Inc. Common Stock (CODX) | $16.04 Million | -756.07% | 0.34x | $1.40 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more